Has John Howard, MD received payments from drug or device companies?

Yes. Drug and device makers reported $854,296 in general payments to John Howard, MD across 136 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Howard, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Howard, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Howard, MD

Surgical Oncology · Mobile, ALNPI 1952515736

Payments from drug & device makers

$854,296in general payments, 2019–2025

Across 136 payments — averaging $6281.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$852K
Regeneron Healthcare Solutions, Inc.$329
Eisai Inc.$226
Johnson & Johnson$165
Incyte Corporation$136
E.r. Squibb & Sons, L.L.C.$109
plus $1K from 40 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	28	$852,014
Regeneron Healthcare Solutions, Inc.	10	$329
Eisai Inc.	13	$226
Johnson & Johnson	9	$165
Incyte Corporation	6	$136
E.r. Squibb & Sons, L.L.C.	1	$109
AstraZeneca(2 entities)	6	$101
AbbVie	3	$83
Taiho Oncology, Inc.	4	$72
Histosonics, Inc.	1	$71
Genentech USA, Inc.	4	$71
Tempus AI, Inc	4	$63
Stemline Therapeutics Inc.	3	$59
Novartis	3	$57
Dendreon Pharmaceuticals LLC	2	$48
ADC Therapeutics America, Inc.	2	$45
Sobi, Inc	2	$39
Pharmacosmos Therapeutics Inc.	2	$35
Lilly USA, LLC	2	$34
Immunogen, Inc.	2	$34
Amgen	2	$33
Daiichi Sankyo Inc.	2	$30
Bayer	2	$30
Exelixis Inc.	1	$29
Blueprint Medicines Corporation	1	$28
Coherus Oncology, Inc.	1	$27
Misonix Inc	1	$23
Seagen Inc.	1	$22
Beigene USA, Inc.	1	$19
Tersera Therapeutics LLC	1	$18
Heron Therapeutics, Inc.	1	$18
Acacia Pharma Inc	1	$17
Springworks Therapeutics, Inc.	1	$17
Syndax Pharmaceuticals, Inc.	1	$17
Novo Nordisk	1	$16
Pharmaessentia USA Corporation	1	$16
Rigel Pharmaceuticals, Inc.	1	$16
Genmab U.S., Inc.	1	$15
EMD Serono, Inc.	1	$15
Sumitomo Pharma America, Inc.	1	$15
Puma Biotechnology, Inc.	1	$15
Myriad Genetic Laboratories, Inc.	1	$14
AVEO Pharmaceuticals, Inc.	1	$14
Beone Medicines USA, Inc.	1	$14
Mirati Therapeutics, Inc.	1	$14
Morphosys, US Inc.	1	$13

How this compares

$854,296 in reported general payments places this provider in the 95th percentile of 26 surgical oncology providers in Alabama.

See all surgical oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$115,940

Medicare patients

156

Services billed

556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Mobile

Joe LilesMobile$4K
Udai SibiaMobile$3K
Natalie BathMobile$2K
Mercy JimenezMobile$2K
Martin HeslinMobile$1K
Lee ThompsonMobile$1K
Rachel HunterMobile$910
Jillian McCabeMobile$817
Sophie DreamBirmingham$39K
Annabelle FonsecaBirmingham$10K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →